PubRank

A Zivelin

Author PubWeight™ 51.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1999 5.34
2 Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998 2.34
3 Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984 2.26
4 One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995 2.05
5 Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998 1.71
6 Point mutations regarded as missense mutations cause splicing defects in the factor XI gene. J Thromb Haemost 2011 1.46
7 A plasma protein C activity assay suitable for a clinical laboratory. Its use to measure activity in hereditary and acquired deficiency states. Am J Clin Pathol 1987 1.44
8 Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 1985 1.13
9 Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992 1.09
10 The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001 1.06
11 The two common mutations causing factor XI deficiency in Jews stem from distinct founders: one of ancient Middle Eastern origin and another of more recent European origin. Blood 1997 1.03
12 Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999 1.01
13 Combined factor V and factor VIII deficiency among non-Ashkenazi Jews. N Engl J Med 1982 1.00
14 Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost 2000 0.97
15 Thrombophilia as a multigenic disorder. Thromb Haemost 1997 0.97
16 Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 2003 0.94
17 Linkage of combined factors V and VIII deficiency to chromosome 18q by homozygosity mapping. J Clin Invest 1997 0.94
18 ERGIC-53 gene structure and mutation analysis in 19 combined factors V and VIII deficiency families. Blood 1999 0.93
19 Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection. Br J Haematol 1986 0.92
20 Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 (Leu33Pro) polymorphism. Stroke 2001 0.91
21 Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coagul Fibrinolysis 1998 0.86
22 Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989 0.86
23 Hereditary deficiency of all vitamin K-dependent procoagulants and anticoagulants. Br J Haematol 1990 0.85
24 Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem 2001 0.85
25 Methionine synthase A2756G and methylenetetrahydrofolate reductase A1298C polymorphisms are not risk factors for idiopathic venous thromboembolism. Hematol J 2001 0.84
26 Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost 2006 0.83
27 Bleeding predictors in factor-XI-deficient patients. Blood Coagul Fibrinolysis 1997 0.83
28 A common ancestral mutation (C128X) occurring in 11 non-Jewish families from the UK with factor XI deficiency. J Thromb Haemost 2004 0.82
29 Identification of a region in glycoprotein IIIa involved in subunit association with glycoprotein IIb: further lessons from Iraqi-Jewish Glanzmann thrombasthenia. Blood 2001 0.81
30 Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009 0.81
31 Factor XIII deficiency due to a Leu660Pro mutation in the factor XIII subunit-a gene in three unrelated Palestinian Arab families. Thromb Haemost 1997 0.81
32 Immunoblot analysis of platelet glycoprotein IIb in patients with Glanzmann thrombasthenia in Israel. Br J Haematol 1989 0.81
33 A relatively high frequency of severe (type III) von Willebrand's disease in Israel. Br J Haematol 1986 0.79
34 Glanzmann thrombasthenia caused by an 11.2-kb deletion in the glycoprotein IIIa (beta3) is a second mutation in Iraqi Jews that stemmed from a distinct founder. Blood 1997 0.78
35 Decreased factor VIII clotting antigen levels in the combined factor V and VIII deficiency. Thromb Res 1984 0.78
36 Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis. Blood 1996 0.77
37 Three residues at the interface of factor XI (FXI) monomers augment covalent dimerization of FXI. J Thromb Haemost 2009 0.77
38 Type I mutation in the F11 gene is a third ancestral mutation which causes factor XI deficiency in Ashkenazi Jews. J Thromb Haemost 2013 0.77
39 Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody. Thromb Haemost 1994 0.77
40 Mutations in the alphaIIb and beta3 genes that cause Glanzmann thrombasthenia can be distinguished by a simple procedure using transformed B-lymphocytes. Thromb Haemost 1998 0.77
41 Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia 2008 0.77
42 Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study. Haemophilia 2013 0.77
43 The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989 0.77
44 Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa-dependent plasma inhibitor of factor VIIa/tissue factor). Thromb Res 1987 0.76
45 Familial factor VII deficiency with foetal and neonatal fatal cerebral haemorrhage associated with homozygosis to Gly180Arg mutation. Haemophilia 2009 0.76
46 Intermittent, dose-related fluctuations of pain and ST elevation during infusion of recombinant tissue plasminogen activator during acute myocardial infarction. Am J Cardiol 1989 0.76
47 The inheritance of type I and type III von Willebrand's disease in Israel: linkage analysis, carrier detection and prenatal diagnosis using three intragenic restriction fragment length polymorphisms. Blood Coagul Fibrinolysis 1992 0.76
48 Do platelets synthesize factor XI? J Thromb Haemost 2004 0.75
49 Patterns of incorporation of 75 Se-methionine into fibrinogen and other plasma proteins in rabbits stimulated by different test conditions. Thromb Diath Haemorrh 1973 0.75
50 Factor VII in plasma of women taking oral contraceptives. Lack of cold activation under blood bank conditions. Transfusion 1984 0.75
51 Seven novel mutations in the factor XIII A-subunit gene causing hereditary factor XIII deficiency in 10 unrelated families. J Thromb Haemost 2004 0.75
52 Purpura fulminans induced by disseminated intravascular coagulation following infection in 2 unrelated children with double heterozygosity for factor V Leiden and protein S deficiency. Thromb Haemost 1997 0.75
53 Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor. Br J Haematol 1997 0.75
54 Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance. Am J Hematol 1995 0.75
55 Combined factors V and VIII deficiency--the solution. Haemophilia 1998 0.75
56 The prevalence of factor V G1691A but not of prothrombin G20210A and methylenetetrahydrofolate reductase C677T is remarkably low in French Basques. J Thromb Haemost 2004 0.75
57 Characterization of mutations causing factor VII deficiency in 61 unrelated Israeli patients. J Thromb Haemost 2004 0.75
58 Hereditary factor XIII deficiency: report of four families and definition of the carrier state. Br J Haematol 1984 0.75
59 [Resistance to activated protein C--a novel cause of thrombophilia]. Harefuah 1995 0.75
60 Molecular characterization of four novel mutations causing factor VII deficiency. Hematol J 2000 0.75
61 A 14-bp deletion (codon 554 del AAGgtaacagagtg) at exon 14/intron N junction of the coagulation factor XI gene disrupts splicing and causes severe factor XI deficiency. Hum Mutat 1996 0.75
62 Fibrinogen response to turpentine and endotoxin in busulfan-treated rabbbits. Thromb Haemost 1976 0.75
63 Detection of Haemophilia A carriers by replicate factor VIII activity and factor VIII antigenicity determinations. Br J Haematol 1979 0.75
64 Fibrinogen levels after inflammation or endotoxin in normal and hypophysectomized rats. Am J Physiol 1975 0.75
65 Cold-promoted activation of factor VII: is It a problem under blood bank conditions? Haemostasis 1983 0.75